abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

这页面没有简体中文版本,现以English显示

文章

2007年3月14日

作者:
Associated Press

Abbott Laboratories won't introduce new drugs in Thailand due to breaking of patent

...Abbott Laboratories said it has decided not to launch new medicines in Thailand in response to the government's decision not to honor the company's patent for its AIDS-fighting drug [Kaletra]. "Thailand has revoked the patent on our medicine, ignoring the patent system. Under these circumstances, we have elected not to introduce new medicines there," said Dirk Van Eeden, public affairs director of Abbott International...Activists accused Abbott of depriving poor people of lifesaving medications. "...I am horrified ... Abbott has the hubris to blacklist a courageous country like Thailand simply trying to do the right thing for its people," said Michael Weinstein, the president of the AIDS Healthcare Foundation...[also refers to Sanofi-Aventis and Bristol-Myers Squibb]